EE05385B1 - LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon - Google Patents

LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon

Info

Publication number
EE05385B1
EE05385B1 EEP200300381A EEP200300381A EE05385B1 EE 05385 B1 EE05385 B1 EE 05385B1 EE P200300381 A EEP200300381 A EE P200300381A EE P200300381 A EEP200300381 A EE P200300381A EE 05385 B1 EE05385 B1 EE 05385B1
Authority
EE
Estonia
Prior art keywords
ákuiáhiváprotease
áamino
useunited
sulphonamides
benzothiazole
Prior art date
Application number
EEP200300381A
Other languages
English (en)
Estonian (et)
Inventor
Dominique�Louis�Nestor�Ghislain�Surleraux
Piet�Tom�Bert�Paul�Wigerinck
Daniel�Getman
Wim�Gaston�Verschueren
Sandrine�Marie�Helene�Vendeville
Marie-Pierre�T.M.M.G�De�Bethune
Jan�Octaaf�Antoon�De�Kerpel
Samuel�Leo�Christiaan�Moors
Herman�Augustinus�De�Kock
Marieke�Christiane�Johanna�Voets
Original Assignee
Tibotec�Pharmaceuticals�Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec�Pharmaceuticals�Ltd. filed Critical Tibotec�Pharmaceuticals�Ltd.
Publication of EE200300381A publication Critical patent/EE200300381A/xx
Publication of EE05385B1 publication Critical patent/EE05385B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200300381A 2001-02-14 2002-02-14 LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon EE05385B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01200529 2001-02-14
US28775801P 2001-05-02 2001-05-02
PCT/EP2002/001788 WO2002083657A2 (en) 2001-02-14 2002-02-14 Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors

Publications (2)

Publication Number Publication Date
EE200300381A EE200300381A (et) 2003-12-15
EE05385B1 true EE05385B1 (et) 2011-02-15

Family

ID=26076833

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300381A EE05385B1 (et) 2001-02-14 2002-02-14 LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon

Country Status (31)

Country Link
US (1) US7659404B2 (zh)
EP (1) EP1370543B1 (zh)
JP (1) JP4530612B2 (zh)
KR (1) KR100870184B1 (zh)
CN (2) CN100369904C (zh)
AP (1) AP1504A (zh)
AT (1) ATE343567T1 (zh)
AU (1) AU2002302363B2 (zh)
BG (1) BG66301B1 (zh)
BR (1) BR0207862A (zh)
CA (1) CA2438304C (zh)
CY (1) CY1108073T1 (zh)
CZ (1) CZ304273B6 (zh)
DE (1) DE60215623T2 (zh)
DK (1) DK1370543T3 (zh)
EA (1) EA006096B1 (zh)
EE (1) EE05385B1 (zh)
ES (1) ES2275866T3 (zh)
HK (1) HK1061233A1 (zh)
HR (1) HRP20030735B1 (zh)
HU (1) HU229224B1 (zh)
IL (2) IL157171A0 (zh)
MX (1) MXPA03007236A (zh)
NO (1) NO326174B1 (zh)
NZ (1) NZ527391A (zh)
PL (1) PL213327B1 (zh)
PT (1) PT1370543E (zh)
SI (1) SI1370543T1 (zh)
SK (1) SK287582B6 (zh)
WO (1) WO2002083657A2 (zh)
ZA (1) ZA200306086B (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU783235B2 (en) 1999-05-28 2005-10-06 Virco Bvba New mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance
AU2631602A (en) 2000-10-20 2002-04-29 Virco Nv New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
BR0207862A (pt) 2001-02-14 2004-06-22 Tibotec Pharm Ltd Inibidores de protease de hiv 2-(amino-substituìda)-benzotiazol-sulfonamida de amplo espectro
AU2003202914A1 (en) 2002-01-07 2003-07-24 Sequoia Pharmaceuticals Broad spectrum inhibitors
US7157489B2 (en) 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
CA2490764C (en) 2002-07-01 2011-11-22 Tibotec Pharmaceuticals Ltd. New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
DE60327768D1 (de) 2002-07-01 2009-07-09 Tibotec Pharm Ltd Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
KR20050025647A (ko) * 2002-08-02 2005-03-14 티보텍 파마슈티칼즈 리미티드 광범위 2-아미노-벤조티아졸 설폰아미드 ｈｉｖ프로테아제 저해제
CN101445493A (zh) * 2002-08-02 2009-06-03 泰博特克药品有限公司 广谱2-氨基-苯并噻唑磺酰胺类hiv蛋白酶抑制剂
ATE353323T1 (de) * 2003-09-30 2007-02-15 Tibotec Pharm Ltd Verfahren zur herstellung von benzoxazolsulfonamidverbindungen und zwischenprodukten davon
DE10360835A1 (de) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
EP2422781A1 (en) * 2004-05-07 2012-02-29 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
AU2006217922B2 (en) 2005-02-25 2012-04-05 Janssen Sciences Ireland Uc Protease inhibitor precursor synthesis
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
JO2841B1 (en) * 2006-06-23 2014-09-15 تيبوتيك فارماسيوتيكالز ليمتد 2-(substituted-amino) -benzothiazole sulfonamide as protease inhibitors HIV (HIV)
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
JO3090B1 (ar) * 2009-12-11 2017-03-15 Janssen Sciences Ireland Uc 5- امينو-4- هيدروكسي-بنتويل اميدات
US9024038B2 (en) * 2010-12-27 2015-05-05 Purdue Research Foundation Compunds and methods for treating HIV
ES2571479T3 (es) 2012-04-20 2016-05-25 Gilead Sciences Inc Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
CN104000824B (zh) * 2014-05-28 2016-07-06 中山大学 苯并五元杂环类化合物在制备抗hiv-1病毒药物中的应用
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0445926B1 (en) 1990-03-09 1996-08-21 Milliken Research Corporation Organic materials having sulfonamido linked poly(oxyalkylene) moieties and their preparation
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ES2123065T3 (es) 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
DE69415326T2 (de) * 1993-08-24 1999-06-02 G.D. Searle & Co., Chicago, Ill. Hydroxyaminosulfonamide verwendbar als inhibitoren retroviraler proteasen
IL111080A (en) 1993-10-01 1999-08-17 Astra Ab Method for treating a finely divided powder medicament
JP4014220B2 (ja) 1995-01-20 2007-11-28 ジー．ディー．サール アンド カンパニー ビス−スルホンアミドヒドロキシエチルアミノ レトロ ウイルスプロテアーゼインヒビター
US6140505A (en) * 1995-03-10 2000-10-31 G. D. Searle & Co. Synthesis of benzo fused heterocyclic sulfonyl chlorides
US5756533A (en) * 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) * 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
RU2174519C2 (ru) * 1995-03-10 2001-10-10 Джи. Ди. Сирл Энд Ко. Гидроксиэтиламино сульфонамиды гетероциклокарбонил аминокислоты, ингибирующие ретровирусную протеазу
US6143788A (en) * 1995-03-10 2000-11-07 G.D. Searle & Co. Bis-amino acid hydroxyethlamino sulfonamide retroviral protease inhibitors
US6861539B1 (en) * 1995-03-10 2005-03-01 G. D. Searle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
WO1997018205A1 (en) 1995-11-15 1997-05-22 G.D. Searle & Co. Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
CN1165291C (zh) 1996-05-20 2004-09-08 詹森药业有限公司 具有改进的生物利用度的抗真菌组合物
HU224217B1 (hu) 1997-03-26 2005-06-28 Janssen Pharmaceutica N.V. Gombaellenes hatóanyaggal és polimerrel bevont magrészt tartalmazó pelletek
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
BR9814484A (pt) * 1997-12-24 2000-10-10 Vertex Pharma "pró-drogas de inibidores de aspartil protease"
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
DK1086076T3 (da) * 1998-06-19 2005-03-29 Vertex Pharma Sulfonamidinhibitorer af aspartylprotease
WO1999067254A2 (en) 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Multi-drug resistant retroviral protease inhibitors and use thereof
WO1999067417A2 (en) * 1998-06-23 1999-12-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Fitness assay and associated methods
AR031520A1 (es) * 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
BR0207862A (pt) 2001-02-14 2004-06-22 Tibotec Pharm Ltd Inibidores de protease de hiv 2-(amino-substituìda)-benzotiazol-sulfonamida de amplo espectro

Also Published As

Publication number Publication date
IL157171A0 (en) 2004-02-08
HK1061233A1 (en) 2004-09-10
BG66301B1 (bg) 2013-03-29
WO2002083657A3 (en) 2003-02-13
AU2002302363B2 (en) 2008-05-01
DE60215623D1 (de) 2006-12-07
ZA200306086B (en) 2005-01-26
ES2275866T3 (es) 2007-06-16
CZ304273B6 (cs) 2014-02-12
KR20030077017A (ko) 2003-09-29
SK287582B6 (sk) 2011-03-04
HUP0303257A2 (hu) 2004-01-28
HRP20030735B1 (en) 2012-02-29
EA006096B1 (ru) 2005-08-25
CN100369904C (zh) 2008-02-20
PT1370543E (pt) 2007-02-28
PL363778A1 (en) 2004-11-29
JP2004518767A (ja) 2004-06-24
CA2438304C (en) 2011-04-12
KR100870184B1 (ko) 2008-11-24
US7659404B2 (en) 2010-02-09
EE200300381A (et) 2003-12-15
EA200300891A1 (ru) 2004-02-26
NO20033584D0 (no) 2003-08-13
NZ527391A (en) 2005-04-29
EP1370543B1 (en) 2006-10-25
CN1525962A (zh) 2004-09-01
WO2002083657A2 (en) 2002-10-24
DE60215623T2 (de) 2007-08-30
SI1370543T1 (sl) 2007-04-30
HRP20030735A2 (en) 2005-08-31
BR0207862A (pt) 2004-06-22
ATE343567T1 (de) 2006-11-15
HU229224B1 (en) 2013-09-30
JP4530612B2 (ja) 2010-08-25
NO20033584L (no) 2003-10-14
IL157171A (en) 2012-10-31
SK11022003A3 (sk) 2004-07-07
CN101230067B (zh) 2011-06-15
EP1370543A2 (en) 2003-12-17
BG108143A (en) 2004-07-30
CZ20032415A3 (cs) 2004-04-14
MXPA03007236A (es) 2003-12-04
NO326174B1 (no) 2008-10-13
CA2438304A1 (en) 2002-10-24
CY1108073T1 (el) 2014-02-12
DK1370543T3 (da) 2007-02-19
AP1504A (en) 2005-12-10
CN101230067A (zh) 2008-07-30
AP2003002856A0 (en) 2003-09-30
PL213327B1 (pl) 2013-02-28
US20040116485A1 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
EE05385B1 (et) LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon
NO20033556D0 (no) Farmasöytiske preparater
DK1478339T3 (da) Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf
IS7714A (is) Lyfjasamsetningar úr módafíníl
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
NO20033384D0 (no) Farmasöytisk formulering
NO20040356L (no) Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling.
NO20033785D0 (no) Farmasöytisk formulering
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20041272L (no) Tetracycline derivatives and methods of use thereof
IL160108A0 (en) Pharmaceutical compositions containing beta-lapachone or derivatives or analogs thereof, and methods of using same
NO20040268L (no) Nye 2H-pyridazin-3-derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen
IS2707B (is) Nýjar lyfjasamsetningar úr módafíníli
NO20044916L (no) Preparater av sulfinylacetamid
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20033506L (no) Parasitticidale preparater og metoder for anvendelse
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
EE200300501A (et) Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid
EE05384B1 (et) LaiaspektrilisedÁ2-(asendatudÁamino)bensoksasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁkasutamine,ÁfarmatseutilineÁkompositsioonÁjaÁmeetodÁretroviiruseÁreplikatsiooniÁinhibeerimiseks
DK1407780T3 (da) Farmaceutisk stabile hæmostatiske præparater
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
NO331227B1 (no) Lineaere basiske forbindelser som har NK-2 antagonistaktivitet, farmasoytiske formuleringer derav og anvendelse av samme for fremstilling av farmasoytiske formuleringer
IS2331B (is) 2-arýlimínó-2,3-díhýdróþíasólafleiður, aðferðir til að framleiða þær og meðferðarfræðileg notkun þeirra
NO20035146L (no) Granulaere preparater av gaboksadol

Legal Events

Date Code Title Description
HE1A Change of address
HE1A Change of address
MM4A Lapsed by not paying the annual fees

Effective date: 20160214